Galectin Therapeutics Inc. · NASDAQ:GALT
Galectin Therapeutics — PRO Pharmaceuticals — BIO Investor Forum 2006
22 slides from Galectin Therapeutics's conference presentation, Oct 20, 2006
Slide 1: Pro-Pharmaceuticals, Inc. - Advancing Drugs Through Glycoscience
www.Pro-Pharmaceuticals.com Amex: PRW A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E® P R O P H A R M A C E U T I C A L S , I N C . Exhibit 99.1
Slide 2: DAVANAT proprietary polysaccharide galactomannan
P R O P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W 8 • Proprietary polysaccharide galactomannan (GM) polymer consisting of galactose units attached to a mannan backbone • Derived from seeds of the plant Cyamopsis tetragonoloba
Slide 3: Slide 3
Slide 4: sl a
* “ . “ sl a —_ = <
Slide 5: sl a
* “ . “ sl a —_ = <
Slide 6: sl a
* “ . “ sl a —_ = <
Slide 7: Pre-clinical Studies: Effect of DAVANAT/5-FU on Tumor Size
P R O P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W 12 CONTROL Pre-clinical Studies Increasing Efficacy: Effect of DAVANAT ® /5-FU on Tumor Size SRI Inc. Experiments 5-FU (alone) DAVANAT ® /5-FU TUMOR SIZE (110 MG) AT START OF
Slide 8: Response of HT-29 Human Colon Tumor Xenografts to DAVANAT with 5-FU and Leucovorin
P R O P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W 13 Response of HT-29, Human Colon Tumor Xenografts to DAVANAT® in Combination with 5-FU and Leucovorin Charles River Labs (Dose: I.V., Q4D x 4, of 5-FU: 48 mg/kg; DAVANAT ® :
Slide 9: Response of ZR75-1 Mammary Tumor Xenografts to DAVANAT with Irinotecan
P R O P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W 14 Response of SC ZR75-1,Human Mammary Tumor Xenografts, to dose escalation DAVANAT ® in combination with Irinotecan Southern Research Institute (Dose I.V., Q4D x 4, of IR 40
Slide 10: Response of COLO 205 Colon Tumor Xenografts to DAVANAT with Avastin and 5-FU
P R O P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W 15 Response of COLO 205, Human Colon Tumor Xenografts, to DAVANAT ® Co-Administrated with AVASTIN ® and 5-FU Southern Research Institute (Dose: I.V., Q4D x 4, of 5-FU 50 mg/kg
Slide 11: Technology Platform: CARBOSOME
P R O P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W 16 DAVANAT ® polymer exists as a “3D” structure in solution with lectin targeting units protruding from the mannan backbone Technology Platform: CARBOSOME™
Slide 12: Product Development Pipeline: October '06
P R O P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W Amex: P R W PRODUCT DAVANAT ® / 5-FU/ LV Irinotecan/ Oxaliplatin DAVANAT ® / 5-FU/LV/ Bevacizumab DAVANAT ® / 5-FU PRO-GR 300 DAVANAT ® / 5-FU PRO-NAC 050 17 Product Developme
Slide 13: What is the Clinical Trial Program?
19 What is the Clinical Trial Program?
Slide 14: Phase I Clinical Trial - All Solid Tumors
P R O P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W 20 Phase I Clinical Trial – All Solid Tumors Indication: All solid tumors. End stage patients; minimum 12 weeks to live Objectives: Primary – Safety Secondary – Tumor progress
Slide 15: Phase I Tumor Type Distribution
P R O P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W 21 Phase l Tumor Type Distribution
Slide 16: Phase I Patient Summary
P R O P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W 22 SD Stable Disease PD Progressive Disease NM Non-Measurable Disease Cycles Completed Dose, cycle 2 /m2 1+2 1001 PD 1002 SD 2001 Hepatocellular PD 2002 Hepatocellular SD 3001
Slide 17: Phase II (Third/Fourth Line) Colorectal Cancer Trial
P R O P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W DAVANAT ® /5-FU 24 Phase II (Third/Fourth Line) Colorectal Cancer Trial Indication: Colorectal cancer; Third/fourth line patients. Objectives: Complete/ partial tumor response
Slide 18: Phase II (First Line) Colorectal Cancer Trial
P R O P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W DAVANAT ® / AVASTIN ® / 5-FU / LV 27 Phase II (First Line) Colorectal Cancer Trial Indication: First line treatment of patients with metastatic, unresectable colorectal cancer
Slide 19: Phase II (First Line) Biliary Cancer Trial
P R O P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W DAVANAT ® / 5-FU 29 Phase II (First Line) Biliary Cancer Trial Indication: Biliary cancer (cholangiocarcinoma). First line therapy. Objectives: Complete/ partial tumor respons
Slide 20: Phase III (Second Line) Colorectal Cancer Trial
P R O P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W 31 Phase lll (Second Line) Colorectal Cancer Trial FOLFOX+DAVANAT ® FOLFOX FOLFIRI FOLFIRI +DAVANAT ® Indication: Metastatic colorectal cancer; Second-line therapy. Objectives
Slide 21: Company & Management
32 Company & Management
Slide 22: Corporate Overview
P R O P H A R M A C E U T I C A L S , I N C. A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E ® Amex: P R W 33 • Founded: July 2000 • Capital raised: $36M (cumulative ) • Inception to Phase ll: $26M • Cash: $9.7M (06/30/06) • Burn rate: $2M per quarter • Shares outstanding: 28M (08/